teleo-codex/domains/health/atypical-anorexia-creates-invisible-glp1-contraindication-through-normal-weight-presentation.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	supports	related
claim	health	The highest-risk population for GLP-1 harm overlaps with the typical candidate appearance, creating systematic under-detection	experimental	NPR Health, February 2026, clinical expert interviews identifying atypical anorexia as 'at high risk of being harmed'	2026-05-04	Atypical anorexia creates an invisible GLP-1 contraindication because patients maintain normal weight making restrictive eating disorders undetectable in standard prescribing workflows	vida	health/2026-02-04-npr-glp1-eating-disorders-anorexia-unknown-risks.md	functional	NPR Health	glp1-eating-disorder-screening-recommended-not-mandated-creating-structural-safety-gap	glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive glp1-pre-treatment-eating-disorder-screening-recommended-not-required glp1-anorexia-nervosa-evidence-absent-despite-pharmacovigilance-signal

Atypical anorexia creates an invisible GLP-1 contraindication because patients maintain normal weight making restrictive eating disorders undetectable in standard prescribing workflows

Clinicians identify atypical anorexics as the population 'at high risk of being harmed' by GLP-1s, but this population is structurally invisible in current prescribing workflows. Atypical anorexia is characterized by restrictive eating patterns and anorexia nervosa psychology but with maintained normal weight (unlike classic anorexia where low BMI is diagnostic). This creates a detection problem: GLP-1s are now prescribed primarily for weight management to patients who appear to have normal or elevated weight, which is exactly the presentation of atypical anorexia. Without systematic psychiatric screening (which as documented above essentially never happens), prescribers cannot distinguish between a patient seeking medically appropriate weight management and a patient with an undiagnosed restrictive eating disorder. The source notes that doctors 'may not recognize the condition' because the normal weight presentation doesn't trigger clinical suspicion. Given that GLP-1s 'suppress natural hunger cues more profoundly' than earlier drugs, prescribing them to patients who are already restricting food intake creates a pharmacological amplification of an existing pathology. This represents a case where the typical candidate appearance (normal or elevated weight seeking reduction) overlaps with the highest-risk contraindicated population (atypical anorexics with normal weight), making harm prevention dependent on screening infrastructure that doesn't exist.